Patents Assigned to The Walter and Eliza Hall Institute of Medical Research
  • Publication number: 20240131028
    Abstract: The present invention relates to a method of chemovaccination against Plasmodium infection comprising administering to a patient an effective amount of a selective inhibitor of plasmepsin X, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 2, 2022
    Publication date: April 25, 2024
    Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research
    Inventors: Justin A. Boddey, David B. Olsen, Ryan Steel, John A. McCauley, Manuel De Lera Ruiz
  • Patent number: 11897864
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: February 13, 2024
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20240043404
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: September 6, 2023
    Publication date: February 8, 2024
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Patent number: 11835520
    Abstract: A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 5, 2023
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Ivo Mueller, Takafumi Tsuboi, Michael White, Rhea Longley
  • Publication number: 20230355622
    Abstract: A method of chemovaccination against Plasmodium infections comprising administering to a patient, an effective amount of a dual inhibitor of plasmepsin IX and X, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 20, 2021
    Publication date: November 9, 2023
    Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research
    Inventors: Justin A. Boddey, David B. Olsen, Ryan Steel
  • Patent number: 11779639
    Abstract: The present disclosure provides mutant parasites, in particular protozoan parasites comprising a mutation of the trehalose-6-phosphate synthase/6-phosphate phosphatase (TPS/TPP)-like gene of Toxoplasma gondii (herein referred to as ‘Toxoplasma’) or a homologue thereof as well as vaccines comprising same.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 10, 2023
    Assignees: The Walter and Eliza Hall Institute of Medical Research, The University of Melbourne
    Inventors: Chris Tonkin, Alessandro Uboldi, Malcolm McConville, Martin Blume
  • Patent number: 11766435
    Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 26, 2023
    Assignees: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research
    Inventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
  • Publication number: 20230201257
    Abstract: Provided herein is a family of programmable de novo designed transmembranal protein domain polypeptides, and uses thereof in the production of engineered chimeric antigen receptor T (CAR T) cells, which are used, for example, to fight cancer.
    Type: Application
    Filed: November 14, 2022
    Publication date: June 29, 2023
    Applicants: Yeda Research and Development Co. Ltd., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Sarel FLEISHMAN, Assaf ELAZAR, Jonathan Y. WEINSTEIN, Melissa J. CALL, Matthew E. CALL, Nicholas J. CHANDLER
  • Publication number: 20230143532
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 7, 2022
    Publication date: May 11, 2023
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Publication number: 20230139282
    Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 4, 2023
    Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research, MSD R&D (China) Co., Ltd.
    Inventors: Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, John A. McCauley, David B. Olsen, Brad Sleebs, Tony Triglia, Dongmei Zhan, Lianyun Zhao
  • Publication number: 20230013692
    Abstract: The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: November 16, 2020
    Publication date: January 19, 2023
    Applicants: Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical Research
    Inventors: John A. McCauley, Manuel de Lera Ruiz, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Dongmei Zhan, Lianyun Zhao
  • Publication number: 20220331321
    Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: July 21, 2020
    Publication date: October 20, 2022
    Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research, MSD R & D (China) Co. LTD.
    Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
  • Publication number: 20220315555
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 6, 2022
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan BRUNCKO, Hong DING, George A. DOHERTY, Steven W. ELMORE, Lisa A. HASVOLD, Laura HEXAMER, Aaron R. KUNZER, Xiaohong SONG, Andrew J. SOUERS, Gerard M. SULLIVAN, Zhi-Fu TAO, Gary T. WANG, Le WANG, Xilu WANG, Michael D. WENDT, Robert MANTEI, Todd M. HANSEN
  • Publication number: 20220267447
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.
    Type: Application
    Filed: April 13, 2022
    Publication date: August 25, 2022
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Patent number: 11326134
    Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: May 10, 2022
    Assignees: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, MELBOURNE HEALTH
    Inventors: Gregory John Tanner, Crispin Alexander Howitt
  • Patent number: 11279760
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: March 22, 2022
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Patent number: 11248034
    Abstract: The present invention relates to insulin analogs, particularly insulin analogs having shortened B chains. The present invention also relates to the crystal structure of insulin from the venom of cone snails and to methods of using the crystal and related structural information to screen for and design insulin analogs that interact with or modulate the insulin receptor. The present invention also relates to therapeutic and prophylactic methods using insulin analogs.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 15, 2022
    Assignees: University of Utah Research Foundation, The Walter and Eliza Hall Institute of Medical Research
    Inventors: John Gerbrandt Tasman Menting, Brian Smith, Danny Hung-Chieh Chou, Helena Safavi-Hemami, Michael Colin Lawrence, Baldomero M. Olivera
  • Publication number: 20220025048
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 27, 2022
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Publication number: 20220025328
    Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.
    Type: Application
    Filed: August 4, 2021
    Publication date: January 27, 2022
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Nicholas D. Huntington, Sandra E. Nicholson
  • Publication number: 20210379020
    Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: August 11, 2021
    Publication date: December 9, 2021
    Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs